Litcius/Paper detail

Circulating PCSK9 as a prognostic biomarker of cardiovascular events in individuals with type 2 diabetes: evidence from a 16.8-year follow-up study

Massimiliano Ruscica, Chiara Macchi, Angelica Giuliani, Alessandra Stefania Rizzuto, Deborah Ramini, Matilde Sbriscia, Stefano Carugo, Anna Rita Bonfigli, Alberto Corsini, Fabiola Olivieri, Jacopo Sabbatinelli

2023Cardiovascular Diabetology44 citationsDOIOpen Access PDF

Abstract

BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality, being twofold to fourfold more common in patients with type 2 diabetes mellitus (T2DM) than in individuals without diabetes. However, despite this decade-old knowledge, the identification of a specific prognostic risk biomarker remains particularly challenging. METHODS: Taking advantage of a large sample of Caucasian patients (n = 529) with a diagnosis of T2DM followed for a median of 16.8 years, the present study was aimed at testing the hypothesis that fasting serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels could be prognostic for major adverse cardiovascular events (MACE) and all-cause mortality. RESULTS: Median levels of PCSK9 were 259.8 ng/mL, being higher in women compared to men and increasing even more in the presence of a complication (e.g., diabetic kidney disease). PCSK9 positively correlated with markers of blood glucose homeostasis (e.g., HbA1c, fasting insulin and HOMA-IR) and the atherogenic lipid profile (e.g., non-HDL-C, apoB and remnant cholesterol). Serum PCSK9 predicted new-onset of MACE, either fatal or non-fatal, only in women (Odds Ratio: 2.26, 95% CI 1.12-4.58) and all-cause mortality only in men (Hazard Ratio: 1.79, 95% CI 1.13-2.82). CONCLUSIONS: Considering that up to two-thirds of individuals with T2DM develop ASCVD in their lifetime, the assessment of circulating PCSK9 levels can be envisioned within the context of a biomarker-based strategy of risk stratification. However, the sex difference found highlights an urgent need to develop sex-specific risk assessment strategies. TRIAL REGISTRATION: It is a retrospective study.

Topics & Concepts

MedicinePCSK9Internal medicineBiomarkerMaceType 2 diabetesDiabetes mellitusHazard ratioContext (archaeology)Type 2 Diabetes MellitusOdds ratioEndocrinologyCholesterolMyocardial infarctionLipoproteinLDL receptorConfidence intervalPercutaneous coronary interventionChemistryPaleontologyBiologyBiochemistryLipoproteins and Cardiovascular HealthCardiac Imaging and DiagnosticsCerebrovascular and Carotid Artery Diseases
Circulating PCSK9 as a prognostic biomarker of cardiovascular events in individuals with type 2 diabetes: evidence from a 16.8-year follow-up study | Litcius